In the Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) trial [11], 10,584 patients with T2D and CKD were randomized to double-blinded therapy with sotagliflozin (200–400 mg/day), which is an SGLT-2 inhibitor that also blocks the gastrointestinal SGLT-1 receptor, or a matching placebo. Here, SLC5A2 is linked to chronic kidney disease.